Volatile Markets Delay the Great IPO Rebound Again Surging volatility grounded the IPO party before it took off, as markets grappled with a tech sell-off, more tariff turmoil, private credit woes, and war in the Middle East in the first quarter of 2026. After ...read more
Thirteen IPOs raised a combined $4.4 billion in February, joined by two direct listings. Deal flow started off strong but stumbled mid-month as concerns around AI disruption sparked a sell-off in tech stocks and recent listings, and heightened volatility led to ...read more
Generate Biomedicines, a Phase 3 biotech using AI to develop therapies for immunology and oncology, raised $400 million by offering 25 million shares at $16, the midpoint of the range of $15 to $17. Generate Biomedicines states that its AI-enabled Generate...read more
Generate Biomedicines, a Phase 3 biotech using an AI drug discovery platform to develop severe asthma therapies, announced terms for its IPO on Monday. The Somerville, MA-based company plans to raise $400 million by offering 25 million shares at a price range...read more
Updated: Renaissance Capital's 1Q 2026 US IPO Market Review
Volatile Markets Delay the Great IPO Rebound Again Surging volatility grounded the IPO party before it took off, as markets grappled with a tech sell-off, more tariff turmoil, private credit woes, and war in the Middle East in the first quarter of 2026. After ...read more
Renaissance Capital's February IPO Market Update
Thirteen IPOs raised a combined $4.4 billion in February, joined by two direct listings. Deal flow started off strong but stumbled mid-month as concerns around AI disruption sparked a sell-off in tech stocks and recent listings, and heightened volatility led to ...read more
Asthma-focused AI biotech Generate Biomedicines prices IPO at $16 midpoint
Generate Biomedicines, a Phase 3 biotech using AI to develop therapies for immunology and oncology, raised $400 million by offering 25 million shares at $16, the midpoint of the range of $15 to $17. Generate Biomedicines states that its AI-enabled Generate...read more
Asthma-focused AI biotech Generate Biomedicines sets terms for $400 million IPO
Generate Biomedicines, a Phase 3 biotech using an AI drug discovery platform to develop severe asthma therapies, announced terms for its IPO on Monday. The Somerville, MA-based company plans to raise $400 million by offering 25 million shares at a price range...read more